1. 104230882 一种度洛西汀盐酸盐杂质的制备方法
CN
08.03.2017
C07D 333/20 Loading...
C07D 333/20
Loading...
201410436429.5
宁波美诺华药业股份有限公司
林祖峰
C07D 333/20
Loading...
本发明涉及一种度洛西汀盐酸盐杂质的制备方法，该方法以度洛西汀游离碱或其盐在酸试剂的存在下，重排一步法，同时制备出了度洛西汀盐酸盐杂质B、C、D及E，且在制备每种杂质时，针对具体物质采用不同的精制方法，使制备所得的每一种杂质都具有较高的纯度，且由于在一个反应中同时制备了杂质B、C、D及E，有效缩短了各种杂质的合成路线。
2. 105395509 一种氯沙坦钾片的制备方法
CN
16.03.2016
A61K 9/28 Loading...
A61K 9/28
Loading...
201510945518.7
宁波美诺华天康药业有限公司
贺慈敏
A61K 9/28
Loading...
本发明涉及一种氯沙坦钾片的制备方法，该方法采用粉末直压工艺制备氯沙坦钾片，对设备无特殊要求，整个制备过程简单安全，便于实现工业化生产；本发明的制备过程中无需使用水或乙醇等作为溶剂，后续过程也无需进行高温烘干，避免了高湿高温环境对主药氯沙坦钾的影响，也避免了氯沙坦钾在干燥过程中随水分或乙醇蒸发而渗透至颗粒表面，有效减小了样品间差异，提高了药品的稳定性；另外，选择合适的氯沙坦钾粒径是本发明成功制备氯沙坦钾片的关键，本发明将氯沙坦钾的粒径设定为54μm≤d(0.5)≤107μm、125μm≤d(0.9)≤278μm，一方面使得氯沙坦钾得以与辅料混合均匀，另一方面，也使得药品个体差异较小，整体稳定性好，氯沙坦钾易于溶出。
3. 104130288 一种替诺福韦酯盐的制备方法
CN
05.11.2014
C07F 9/6561 Loading...
C07F 9/6561
Loading...
201410299026.0
宁波美诺华药业股份有限公司
林祖峰
C07F 9/6561
Loading...
本发明涉及一种替诺福韦酯盐的制备方法，先以替诺福韦或替诺福韦一水合物为起始原料，在强极性有机溶剂中与氯甲基异丙基碳酸酯在相转移催化剂的存在下发生缩合反应制得替诺福韦酯，然后再将替诺福韦酯与琥珀酸或富马酸成盐制得替诺福韦酯盐；在酯化反应脱除有机溶剂阶段，采用薄膜蒸发器蒸馏，在低温下迅速脱除溶剂，物料在蒸发器内流过时间很短，约10秒，避免了现有技术中由于蒸馏温度过高、受热时间过长引起的反应物分解问题，使得产品的纯度及收率都得到很大提高。本发明最终成品的HPLC≥99.85％，单一杂质含量＜0.1％，收率62％～67％。
4. 104003946 Preparation method for erlotinib hydrochloride impurity
CN
27.08.2014
C07D 239/94 Loading...
C07D 239/94
Loading...
201410097800.X
宁波美诺华药业股份有限公司
居鸿江
C07D 239/94
Loading...
The present invention relates to a preparation method for an erlotinib hydrochloride impurity N-(3-vinyl-phenyl)--quinolineamine hydrochloride. Firstly, 6,7-bis-(2-methoxyethoxy)-4(3H)-quinazolinone reacts with an acylating reagent to obtain 4-chloro-6,7-bis-(2-methoxyethoxy)-quinazoline, then the 4-chloro-6,7-bis-(2-methoxyethoxy)-quinazoline reacts with m-aminostyrene to generate the target product N-(3-vinyl-phenyl)--quinolineamine hydrochloride. The present method has characteristics of a short synthetic route, simple operation and high product purity up to 99.77%, and provides conditions for the qualitative and quantitative analysis of impurity in the production of erlotinib hydrochloride, thereby further improving the quality standards of erlotinib hydrochloride and providing guidance for safe medication of people.
5. 103910773 Method for synthesizing capecitabine impurities
CN
09.07.2014
C07H 19/06 Loading...
C07H 19/06
Loading...
201410137442.0
宁波美诺华药业股份有限公司
王元光
C07H 19/06
Loading...
The invention relates to a method for synthesizing capecitabine impurities. The method comprises the following steps: chloridizing 2,3-O-isopropylidene-5-deoxy-D-ribofuranose containing an alpha position and a beta position as a raw material firstly, and then reacting with capecitabine at low temperature under the action of NaH to obtain beta-3-acetonylidene, beta-2-acetonylidene, and alpha-3-acetonylidene; enabling the beta-3-acetonylidene, the beta-2-acetonylidene and the alpha-3-acetonylidene to react in methanol and water under the action of a solid acid catalyst Amberlyst15, so as to obtain a beta-3 impurity, a beta-2 impurity and an alpha-3 impurity. By adopting the method, the beta-3 impurity, the beta-2 impurity and the alpha-3 impurity of the capecitabine are successfully synthesized, and a basis is provided for research of the capecitabine. In the process, three important intermediates, namely the beta-3-acetonylidene, the beta-2-acetonylidene and the alpha-3-acetonylidene are found out. The retention time of the beta-3 impurity, the beta-2 impurity and the alpha-3 impurity obtained by using the synthesis method disclosed by the invention relatively to the capecitabine respectively is 1.054, 1.068 and 1.193.
6. 103896819 一种(S)-1-氯乙酰基吡咯烷-2-甲酰胺的制备方法
CN
02.07.2014
C07D 207/16 Loading...
C07D 207/16
Loading...
201410112710.3
宁波美诺华药业股份有限公司
方为军
C07D 207/16
Loading...
本发明涉及一种(S)-1-氯乙酰基吡咯烷-2-甲酰胺的制备方法，在该制备方法中引入了水性后处理工艺，该处理过程中，缚酸剂所形成的盐通过和碳酸钾反应重新游离出来进入有机层，并在后面的有机层浓缩过程中被去除，而目标产物则始终留置于有机层中，经浓缩后以较纯的固体形式存在，目标产物的纯度达到96%以上；同时，该制备方法操作简单、收率高，收率达到95%以上，适于工业化生产。
7. 103013898 一种表达羰基还原酶的重组工程菌及其应用
CN
03.04.2013
C12N 1/21 Loading...
C12N 1/21
Loading...
201210440849.1
宁波美诺华药业股份有限公司
金志华
C12N 1/21
Loading...
本发明公开了一种表达羰基还原酶的重组工程菌及其应用，该工程菌包括宿主细胞和转入宿主细胞的重组载体，所述重组载体由原始载体及接入原始载体的目的基因构成，所述宿主细胞为大肠杆菌(Escherichiacoli)Rosetta(DE3)，所述的目的基因为羰基还原酶基因，碱基序列如SEQ IDNO.1所示。本发明重组工程菌羰基还原酶表达水平较高，利用诱导培养的菌体细胞将氮，氮-二甲基-3-氧基-3-(2-噻吩)-l-丙胺盐酸盐转化为(S)-氮，氮-二甲基-3-羟基-3-(2-噻吩)-l-丙胺；或将4-氯乙酰乙酸乙酯转化为(S)-4-氯-3-羟基丁酸乙酯，两种产物的光学纯度及转化率均较高。
8. 102925368 一种可催化不对称还原反应的球孢白僵菌及其应用
CN
13.02.2013
C12N 1/14 Loading...
C12N 1/14
Loading...
201210441085.8
浙江大学宁波理工学院
金志华
C12N 1/14
Loading...
本发明公开了一种可催化不对称还原反应的球孢白僵菌(Beauveriabassiana)，该菌株保藏于中国微生物菌种保藏管理委员会普通微生物保藏中心，保存号为：CGMCC NO.6345，保藏时间2012年7月12日。本发明的菌株可以表达高立体选择性的羰基还原酶，利用该菌株进行4-氯乙酰乙酸乙酯的全细胞催化时，产物中S-4-氯-3-羟基丁酸乙酯的对映体过量值达到100％e.e.；利用该菌株进行N，N-二甲基-3-氧代-3-(2-噻吩)-1-丙胺盐酸盐的全细胞催化时，产物中(S)-N，N-二甲基-3-羟基-3-(2-噻吩)-1-丙胺盐酸盐的对映体过量值达到100％e.e.。 CGMCC NO.6345 2012.07.12
9. 102311426 一种奥美沙坦中间体的制备方法
CN
11.01.2012
C07D 403/10 Loading...
C07D 403/10
Loading...
201110277756.7
宁波美诺华药业有限公司
沈瑾志
C07D 403/10
Loading...
本发明公开了一种奥美沙坦中间体的制备方法：将1-溴-4-[2-丙基-4-(1-羟基-1-甲基乙基)-5-羧酸乙酯咪唑基]甲苯在甲苯介质中与2-(5-(1-三苯甲基-1H-四氮唑)苯硼酸在四(三苯基磷)钯和碳酸钾的作用下，75～85℃条件下反应，反应完全后，反应液过滤，得滤饼与滤液，滤饼用水洗后，取有机相浓缩，获得浓缩液，取浓缩液再加热溶解，搅拌析晶，在0～5℃条件下搅拌充分，过滤，滤饼干燥制得奥美沙坦中间体；本发明所采用的催化剂为均相催化剂四(三苯基磷)钯，相比较现有技术，大大降低了催化剂的使用量；所示的奥美沙坦中间产物收率与纯度较高，其所制备的奥美沙坦符合PharmeuropaVo1.22.No.3July，2010质量要求，钯残留量符合ICH小于10ppm的要求；本发明极大地降低了环境的污染，适合工业化生产。
10. 102060860 Preparation method of Marbofloxacin
CN
18.05.2011
C07D 498/06 Loading...
C07D 498/06
Loading...
201110002404.0
Anhui Menovo Pharmaceutical Co., Ltd.
Zhou Guangjun
C07D 498/06
Loading...
The invention discloses a preparation method of Marbofloxacin, which comprises the following steps: (1) mixing a compound disclosed as Formula (V) with phenylmethane, triethylamine and N-methylpiperazine, heating to react for 8-12 hours, cooling to room temperature, adding purified water and potassium hydroxide, reacting at 60-90 DEG C for 3-5 hours, cooling to 20-25 DEG C, separating out a water phase, regulating the pH value of the water phase to 6.8-7.2 with hydrochloric acid, extracting with dichloromethane, and concentrating while depressurizing to obtain a compound disclosed as Formula (IV); and (2) reacting the compound disclosed as Formula (IV) with potassium hydroxide in medium water at 125-160 DEG C under the pressure of 0.1-0.4 MPa for 5-12 hours to obtain a compound disclosed as Formula (II), dropwisely adding a formic acid water solution and a formaldehyde water solution when the temperature drops to 40-50 DEG C, carrying out cyclization reaction at 70-75 DEG C for 6-10 hours, and carrying out after-treatment on the reaction product to obtain the Marbofloxacin. The invention utilizes a new intermediate to prepare Marbofloxacin, has the advantages of short reaction time, low cost and high product purity, and is suitable for commercial production.

